Session » 5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

Date: Tuesday, October 23, 2018

Time: 2:30PM-4:00PM

Meeting: 2018 ACR/ARHP Annual Meeting

Abstract Number: 2838

Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database

Abstract Number: 2839

Microrna Expression in the Vasculitic Skin Lesions of Adult Patients with IgA Vasculitis

Abstract Number: 2840

MiR-125-b Is a Promising Biomarker for Giant Cell Arteritis in Patients with Negative Temporal Artery Biopsy Examination

Abstract Number: 2841

Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup

Abstract Number: 2842

Does Leflunomide Have a Role in Giant Cell Arteritis?

Abstract Number: 2843

Leflunomide in Giant Cell Arteritis and Polymyalgia Rheumatica: A Real World Single Centre Experience

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.